Lumida
/BTSG
⌘K
Brightspring Health Services Inc

Brightspring Health Services Inc

BTSG
$70.69USD↑+3.71%+2.53 today

MARKET CAP

13.9B

P/E (TTM)

53.2x

FWD P/E

38.2x

DAY RANGE

$67 – $71

52W RANGE

$19
$72

AI Summary

Stalk
StalkMedium

BTSG remains in a Stage 2 advancing uptrend with a clear sequence of higher highs and higher lows above rising EMAs. The active Bullish Exhaustion pattern at recent highs and heavier-volume pullback under the 9/21 EMAs signal waning momentum and a tactical pause. Medium-term bias is Bullish, but short-term conditions are unfavorable, warranting a deferred entry into pullbacks near the rising EMA support zone.

  • ↑Q1 2026 revenue reached $3.6 B, up 26% YoY
  • ↑Adjusted EBITDA rose 45% YoY to $190 M
  • ↓P/E ratio of 50.7x implies premium valuation risk
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

BrightSpring Health Services, Inc. (NASDAQ: BTSG) offers a diverse range of healthcare services, with a particular focus on home health, pharmacy solutions, and specialized therapies. The company is positioned as a leader in home and community health, strategically leveraging its scale and operational efficiencies to cater to complex patient populations. BrightSpring's focus on enhancing patient care quality highlights its alignment with the growing trend towards home-based healthcare solutions, especially within the context of an aging population and increasing demand for cost-effective care options.

Bull says

  • ↑Q1 2026 revenue reached $3.6 B, up 26% YoY
  • ↑Adjusted EBITDA rose 45% YoY to $190 M
  • ↑Pharmacy solutions revenue grew 25% YoY to $3.2 B
  • ↑Recent acquisitions add ~$30 M in projected EBITDA
  • ↑Leverage improved to 2.27x, supporting M&A flexibility
  • ↑Analyst upgrades and strong momentum signal undervaluation

Bear says

  • ↓P/E ratio of 50.7x implies premium valuation risk
  • ↓IRA expected to cut pharmacy revenue by $175 M in 2026
  • ↓Debt of ~$2.5 B and 2.27x leverage heightens financial strain
  • ↓Exit of uneconomic customers pressured home pharmacy revenue
  • ↓High stock volatility reflects market uncertainty
  • ↓Negative earnings yield and dividend yield raise return concerns

Investment themes with BTSG

Health Care Providers↓ -0.61%

UNH · CVS · HCA

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-02-2026neutral

Transcript signals

Bull points

  • The market's real dynamic continues to present opportunities, and there's still a healthy stream of drugs that will be coming up on their patent expiration date and converting to generics.
  • Overall, we are pleased with our first quarter financial results with total company revenue of 3.6 billion that grew 26% year over year.
  • Pharmacy Solutions revenue of 3.2 billion and provider services revenue of $442 million represented 25 and 28% growth respectively.

Bear points

  • SG&A stepped up by $40 million sequentially, marking a 40% increase quarter over quarter, which raises concerns about spending efficiency. They must address what is driving this increase and if it's a one-time issue or part of a broader spending trend.
  • Corporate costs was up maybe a little bit more than we thought.
  • Home and community pharmacy revenue was $527 million, representing a decline of 9% year-over-year due to an approximately $50 million impact from the IRA, which was expected, along with our decision to exit any uneconomic customers, both of which we have previously discussed and came in line with our expectations.
Read full transcript analysis ›